1301-P：1 型糖尿病 (T1D) 高危人群中单一自身抗体阳性 (SAB+) 的频率因种族/族裔和地区贫困指数而异

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2024-07-19 DOI:10.2337/db24-1301-p

ANANTA ADDALA, SUSANNE M. CABRERA, DAVID D. CUTHBERTSON, INGRID LIBMAN, MUSTAFA TOSUR, ALEJANDRO F. SILLER, LINDA A. DIMEGLIO, KEVAN C. HEROLD, MARIA J. REDONDO, HEBA M. ISMAIL

{"title":"1301-P：1 型糖尿病 (T1D) 高危人群中单一自身抗体阳性 (SAB+) 的频率因种族/族裔和地区贫困指数而异","authors":"ANANTA ADDALA, SUSANNE M. CABRERA, DAVID D. CUTHBERTSON, INGRID LIBMAN, MUSTAFA TOSUR, ALEJANDRO F. SILLER, LINDA A. DIMEGLIO, KEVAN C. HEROLD, MARIA J. REDONDO, HEBA M. ISMAIL","doi":"10.2337/db24-1301-p","DOIUrl":null,"url":null,"abstract":"Introduction & Objective: The diversity of individuals living with T1D has increased, driven by Hispanic (H) and non-Hispanic Black (NHB) populations. Yet, whether H and NHB populations have different rates of SAB+ than other groups, which can impact clinical care and research opportunities, has not been well characterized. Area deprivation and race/ethnicity are strongly associated with each other and have compounding and adverse effects on diabetes-related health outcomes. We examined TrialNet data from relatives of persons with T1D screened for pancreatic autoantibodies and evaluated the frequency of SAB+ by race/ethnicity and area deprivation. Methods: Persons (n=28330) screened between 4/9/19-12/31/22 were included. Race/ethnicity was categorized as non-Hispanic white (NHW), H, NHB, and non-Hispanic other (NHO). Home address zip codes were used to assign an Area Deprivation Index, a Health and Human Services Administration index incorporating neighborhood income, education, employment, and housing that ranges from 1 (least deprived) to 100 (most deprived). Deprivation was analyzed in quintiles. Results: A majority (80.7%) self-identified as NHW; fewer as H (9.8%), NHB (2.5%), and NHO (7.0%). Deprivation differed by race/ethnicity (NHW 46±23, H: 45±24, NHB: 53±23, and NHO: 39±25, p&lt;0.001). SAB+ was more common in NHB and H than NHO and NHW individuals (Overall: 3.0%, NHB: 4.7%, H: 3.8%, NHO: 3.1%, NWH: 3.0%; χ2 p=0.02). Logistic regression identified a linear relationship between SAB+ and deprivation (Deprivation quintiles 1 to 5: 2.9%, 2.7%, 3.1%, 3.1%, 3.5%; p=0.04). Conclusion: These data suggest SAB+ status varies by both race/ethnicity and deprivation which warrants further investigation. Understanding patterns of autoantibody positivity that occur in diverse populations at risk for T1D is foundational to identifying persons who are SAB+ or in early stages of T1D who may now be eligible for preventive therapies. Disclosure A. Addala: None. S.M. Cabrera: Research Support; Abbott. D.D. Cuthbertson: None. I. Libman: None. M. Tosur: None. A.F. Siller: None. L.A. DiMeglio: Research Support; Dompé, Lilly Diabetes, MannKind Corporation, Medtronic, Provention Bio, Inc., Sanofi, Zealand Pharma A/S, Amgen Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated, Abata Therapeutics. K.C. Herold: Consultant; Sanofi. M.J. Redondo: None. H.M. Ismail: Consultant; Sanofi, Rise Therapeutics.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"340 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D)\",\"authors\":\"ANANTA ADDALA, SUSANNE M. CABRERA, DAVID D. CUTHBERTSON, INGRID LIBMAN, MUSTAFA TOSUR, ALEJANDRO F. SILLER, LINDA A. DIMEGLIO, KEVAN C. HEROLD, MARIA J. REDONDO, HEBA M. ISMAIL\",\"doi\":\"10.2337/db24-1301-p\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction & Objective: The diversity of individuals living with T1D has increased, driven by Hispanic (H) and non-Hispanic Black (NHB) populations. Yet, whether H and NHB populations have different rates of SAB+ than other groups, which can impact clinical care and research opportunities, has not been well characterized. Area deprivation and race/ethnicity are strongly associated with each other and have compounding and adverse effects on diabetes-related health outcomes. We examined TrialNet data from relatives of persons with T1D screened for pancreatic autoantibodies and evaluated the frequency of SAB+ by race/ethnicity and area deprivation. Methods: Persons (n=28330) screened between 4/9/19-12/31/22 were included. Race/ethnicity was categorized as non-Hispanic white (NHW), H, NHB, and non-Hispanic other (NHO). Home address zip codes were used to assign an Area Deprivation Index, a Health and Human Services Administration index incorporating neighborhood income, education, employment, and housing that ranges from 1 (least deprived) to 100 (most deprived). Deprivation was analyzed in quintiles. Results: A majority (80.7%) self-identified as NHW; fewer as H (9.8%), NHB (2.5%), and NHO (7.0%). Deprivation differed by race/ethnicity (NHW 46±23, H: 45±24, NHB: 53±23, and NHO: 39±25, p&lt;0.001). SAB+ was more common in NHB and H than NHO and NHW individuals (Overall: 3.0%, NHB: 4.7%, H: 3.8%, NHO: 3.1%, NWH: 3.0%; χ2 p=0.02). Logistic regression identified a linear relationship between SAB+ and deprivation (Deprivation quintiles 1 to 5: 2.9%, 2.7%, 3.1%, 3.1%, 3.5%; p=0.04). Conclusion: These data suggest SAB+ status varies by both race/ethnicity and deprivation which warrants further investigation. Understanding patterns of autoantibody positivity that occur in diverse populations at risk for T1D is foundational to identifying persons who are SAB+ or in early stages of T1D who may now be eligible for preventive therapies. Disclosure A. Addala: None. S.M. Cabrera: Research Support; Abbott. D.D. Cuthbertson: None. I. Libman: None. M. Tosur: None. A.F. Siller: None. L.A. DiMeglio: Research Support; Dompé, Lilly Diabetes, MannKind Corporation, Medtronic, Provention Bio, Inc., Sanofi, Zealand Pharma A/S, Amgen Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated, Abata Therapeutics. K.C. Herold: Consultant; Sanofi. M.J. Redondo: None. H.M. Ismail: Consultant; Sanofi, Rise Therapeutics.\",\"PeriodicalId\":11376,\"journal\":{\"name\":\"Diabetes\",\"volume\":\"340 1\",\"pages\":\"\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2337/db24-1301-p\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-1301-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

引言& 目的：在西班牙裔（H）和非西班牙裔黑人（NHB）人群的推动下，T1D 患者的多样性有所增加。然而，西班牙裔和非西班牙裔黑人的 SAB+ 患病率是否有别于其他群体，这可能会影响临床护理和研究机会，目前还没有很好的定性。地区贫困和种族/人种密切相关，并对糖尿病相关的健康结果产生复合的不利影响。我们研究了 TrialNet 数据，这些数据来自接受胰腺自身抗体筛查的 T1D 患者的亲属，并根据种族/民族和地区贫困程度评估了 SAB+ 的频率。方法：纳入在 4/9/19-12/31/22 期间接受筛查的人（n=28330）。种族/族裔分为非西班牙裔白人 (NHW)、H、NHB 和非西班牙裔其他 (NHO)。家庭住址的邮政编码被用来分配地区贫困指数，该指数是卫生与公众服务管理局（Health and Human Services Administration）综合了社区收入、教育、就业和住房的指数，范围从 1（最贫困）到 100（最贫困）。贫困程度按五等分进行分析。结果显示大多数人（80.7%）自我认同为 NHW；较少人认同为 H（9.8%）、NHB（2.5%）和 NHO（7.0%）。不同种族/族裔的贫困程度不同（NHW 46±23，H：45±24，NHB：53±23，NHO：39±25，p<0.001）。与 NHO 和 NHW 相比，SAB+ 在 NHB 和 H 中更为常见（总体：3.0%，NHB：4.7%，H：3.8%，NHO：3.1%，NWH：3.0%；χ2 p=0.02）。逻辑回归确定了 SAB+ 与贫困之间的线性关系（贫困五分位数 1 至 5：2.9%、2.7%、3.1%、3.1%、3.5%；P=0.04）。结论这些数据表明，SAB+状态因种族/民族和贫困程度而异，值得进一步研究。了解不同T1D高危人群自身抗体阳性的模式，对于识别SAB+患者或T1D早期患者（他们现在可能有资格接受预防性治疗）至关重要。披露 A. Addala：无。S.M. Cabrera：研究支持；雅培。D.D. Cuthbertson：无：无。I. Libman: None.M. Tosur：M. Tosur: None.A.F. Siller：无。L.A. DiMeglio：研究支持；Dompé、Lilly Diabetes、MannKind Corporation、Medtronic、Provention Bio, Inc.、Sanofi、Zealand Pharma A/S、Amgen Inc.顾问团；Vertex Pharmaceuticals Incorporated、Abata Therapeutics。K.C. Herold：赛诺菲顾问。M.J. Redondo：无。H.M. Ismail：顾问；赛诺菲、Rise Therapeutics。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

1301-P: Frequency of Single Autoantibody Positivity (SAB+) Varies by Race/Ethnicity and Area Deprivation Index in Individuals at Risk for Type 1 Diabetes (T1D)

Introduction & Objective: The diversity of individuals living with T1D has increased, driven by Hispanic (H) and non-Hispanic Black (NHB) populations. Yet, whether H and NHB populations have different rates of SAB+ than other groups, which can impact clinical care and research opportunities, has not been well characterized. Area deprivation and race/ethnicity are strongly associated with each other and have compounding and adverse effects on diabetes-related health outcomes. We examined TrialNet data from relatives of persons with T1D screened for pancreatic autoantibodies and evaluated the frequency of SAB+ by race/ethnicity and area deprivation. Methods: Persons (n=28330) screened between 4/9/19-12/31/22 were included. Race/ethnicity was categorized as non-Hispanic white (NHW), H, NHB, and non-Hispanic other (NHO). Home address zip codes were used to assign an Area Deprivation Index, a Health and Human Services Administration index incorporating neighborhood income, education, employment, and housing that ranges from 1 (least deprived) to 100 (most deprived). Deprivation was analyzed in quintiles. Results: A majority (80.7%) self-identified as NHW; fewer as H (9.8%), NHB (2.5%), and NHO (7.0%). Deprivation differed by race/ethnicity (NHW 46±23, H: 45±24, NHB: 53±23, and NHO: 39±25, p<0.001). SAB+ was more common in NHB and H than NHO and NHW individuals (Overall: 3.0%, NHB: 4.7%, H: 3.8%, NHO: 3.1%, NWH: 3.0%; χ2 p=0.02). Logistic regression identified a linear relationship between SAB+ and deprivation (Deprivation quintiles 1 to 5: 2.9%, 2.7%, 3.1%, 3.1%, 3.5%; p=0.04). Conclusion: These data suggest SAB+ status varies by both race/ethnicity and deprivation which warrants further investigation. Understanding patterns of autoantibody positivity that occur in diverse populations at risk for T1D is foundational to identifying persons who are SAB+ or in early stages of T1D who may now be eligible for preventive therapies. Disclosure A. Addala: None. S.M. Cabrera: Research Support; Abbott. D.D. Cuthbertson: None. I. Libman: None. M. Tosur: None. A.F. Siller: None. L.A. DiMeglio: Research Support; Dompé, Lilly Diabetes, MannKind Corporation, Medtronic, Provention Bio, Inc., Sanofi, Zealand Pharma A/S, Amgen Inc. Advisory Panel; Vertex Pharmaceuticals Incorporated, Abata Therapeutics. K.C. Herold: Consultant; Sanofi. M.J. Redondo: None. H.M. Ismail: Consultant; Sanofi, Rise Therapeutics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.